Accessibility Menu
Genmab A/s logo

Genmab A/s(NASDAQ) GMAB

Market Cap$19.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+820%
5 Year-29%
1 Year+41%
1 Month+15%
$33.60
+1.94%
+0.64Today
Genmab A/s last closing stock price
MetricPriceDate
Last closeUSD 32.962026-08-18
Genmab A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.84%USD 30.852026-08-11
1 month+14.76%USD 28.722026-07-17
3 month+21.13%USD 27.212026-05-20
Year to date+7.01%USD 30.802025-12-31
1 year+40.73%USD 23.422025-08-18
3 year-9.18%USD 36.292023-08-18
5 year-28.97%USD 46.402021-08-19
Since inception+819.9%USD 3.582013-06-03

Genmab A/s Financials at a Glance

Market Cap

$19.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.13B

Net Income (TTM)

$788.10M

EPS (TTM)

$1.26

P/E Ratio

25.78

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$33.60

Volume

148,471.233

Open

$33.41

Previous Close

$32.96

Daily Range

$33.26 - $33.51

52-Week Range

$23.62 - $35.43

Estimated Earnings Date

Nov 5, 2026

GMAB News

Person checking medicine on a shelf in a pharmacy

Why Genmab Stock Popped on Friday

Eric VolkmanOct 3, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Was Marching Higher Today

Eric VolkmanSep 30, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Smashed It on Monday

Eric VolkmanJun 2, 2025
DNA genetic sequencing biotech.jpg

Genmab Revenue Surges 18% in Q3

Motley Fool Markets TeamNov 6, 2024
cash-prescription-drugs-getty

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Cory RenauerJun 10, 2020
stock chart

Are There Good Investments Among 2019's Biotech IPOs?

David HaenOct 2, 2019

GMAB: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Genmab A/S is a biopharmaceutical company based in Copenhagen, Denmark, specializing in the discovery and development of innovative antibody therapies for cancer and other serious diseases. Founded in 1999, Genmab has established a strong portfolio of commercialized products and a robust pipeline of investigational medicines.

Products and Services
  • DARZALEX for multiple myeloma and other blood cancers
  • Teprotumumab for thyroid eye disease
  • Amivantamab for advanced gastric and lung cancers
Growth Outlook
  • Recent quarterly revenue reached $1.155 billion, indicating strong market demand
  • Pipeline includes several products in late-stage clinical trials, enhancing future revenue potential
  • Strategic collaborations with major pharmaceutical companies support ongoing research and development
Financial Highlights
  • Net income for Q2 2026 was $303 million, reflecting solid profitability
  • Operating income margin of 35.2% demonstrates efficient cost management
  • Cash and short-term investments totaled $1.5 billion, providing financial stability
Genmab A/S has positioned itself as a leader in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. The company's strong financial performance, highlighted by significant revenue growth and profitability, underscores its potential for future expansion. With a diverse product portfolio and a promising pipeline, Genmab is well-equipped to capitalize on opportunities in the biopharmaceutical market. Strategic partnerships further enhance its research capabilities, making it an attractive option for investors interested in the healthcare sector.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,119

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, CD 2500, DK

GMAB Financials

Key Financial Metrics (TTM)

Gross Margin

39.92%

Operating Margin

13.81%

Net Income Margin

8.17%

Return on Equity

13.58%

Return on Capital

11.11%

Return on Assets

6.30%

Earnings Yield

3.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

597.02M

Volume

148.47K

Avg. Volume

2.10M

Financials (TTM)

Gross Profit

$3.84B

Operating Income

$1.33B

EBITDA

$1.22B

Operating Cash Flow

$890.35M

Capital Expenditure

-$23.00M

Free Cash Flow

$867.34M

Cash & ST Invst.

$1.50B

Total Debt

$5.27B

Genmab A/s Performance Analysis

Genmab A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,049,135,24452.0%
20232023-12-31USD 2,390,322,51516.7%
20242024-12-31USD 3,121,756,72930.6%
20252025-12-31USD 3,731,385,66719.5%
Genmab A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3010.5%
Q42025-12-313.2%
Q12026-03-31-14.7%
Q22026-06-3028.4%
Genmab A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.1761.2%
20232023-12-31USD 0.96-17.9%
20242024-12-31USD 1.7683.7%
20252025-12-31USD 1.54-12.5%
Genmab A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.4%
Q42025-12-31-92.9%
Q12026-03-3180.4%
Q22026-06-30490.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.16B

+24.9%

Gross Profit

$1.07B

+23.4%

Gross Margin

92.73%

N/A

Market Cap

$19.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.37M

N/A

Employees

3,088

N/A

Net Income

$303.00M

-9.8%

EBITDA

$431.00M

-3.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.50B

-48.1%

Total Debt

$5.27B

+3463.6%

Accounts Receivable

$1.28B

+28.3%

Inventory

$18.00M

+38.5%

Long Term Debt

$4.96B

+3659.1%

Short Term Debt

$312.00M

+1850.4%

Return on Assets

6.30%

N/A

Return on Invested Capital

11.71%

N/A

Free Cash Flow

$48.00M

-7.7%

Operating Cash Flow

$51.00M

-17.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZBHZimmer Biomet Holdings, Inc.
$101.13+1.99%
THCTenet Healthcare Corporation
$275.42+1.93%
UTHRUnited Therapeutics Corporation
$532.35+2.72%
INCYIncyte Corporation
$125.49+1.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$119.00+0.89%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$20.22+0.13%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.51-0.04%
TNONTenon Medical
$10.77+0.98%

Questions About GMAB

What is the current price of Genmab A/s?

Genmab A/s is trading at $33.29 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between $23.62 and $35.43.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $5.27B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.50B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services